



FEP Medical Policy Manual

FEP 6.01.65 Oncologic Applications of Positron Emission Tomography Scanning (Lung)

Annual Effective Policy Date: October 1, 2024

Original Policy Date: September 2024

Related Policies:

- 6.01.06 - Miscellaneous (Noncardiac, Nononcologic) Applications of Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography
- 6.01.20 - Cardiac Applications of Positron Emission Tomography Scanning
- 6.01.51 - Interim Positron Emission Tomography Scanning in Oncology to Detect Early Response During Treatment
- 6.01.62 - Oncologic Applications of Positron Emission Tomography Scanning (Breast and Gynecologic)
- 6.01.63 - Oncologic Applications of Positron Emission Tomography Scanning (Bone and Sarcoma)
- 6.01.64 - Oncologic Applications of Positron Emission Tomography Scanning (Hematologic)
- 6.01.65 - Oncologic Applications of Positron Emission Tomography Scanning (Lung)
- 6.01.66 - Oncologic Applications of Positron Emission Tomography Scanning (Thyroid, Neuroendocrine, Head and Neck)
- 6.01.67 - Oncologic Applications of Positron Emission Tomography Scanning (Brain, Melanoma, Unknown Primary)

Oncologic Applications of Positron Emission Tomography Scanning (Lung)

Description

Description

Positron emission tomography (PET) scans are based on the use of positron-emitting radionuclide tracers coupled to organic molecules, such as glucose, ammonia, or water. The radionuclide tracers simultaneously emit 2 high-energy photons in opposite directions that can be simultaneously detected (referred to as coincidence detection) by a PET scanner, comprising multiple stationary detectors that encircle the area of interest.

OBJECTIVE

The objective of this evidence review is to determine whether the use of positron emission tomography for the diagnosis, staging and restaging, and/or surveillance improves the net health outcome in individuals with lung cancer.

POLICY STATEMENT

Lung Cancer

PET scanning may be considered **medically necessary** for any of the following applications:

- Individuals with a solitary pulmonary nodule as a single scan technique (not dual-time) to distinguish between benign and malignant disease when prior CT scan and chest x-ray findings are inconclusive or discordant,
- As staging or restaging technique in those with known non-small-cell lung cancer, and
- To determine resectability for individuals with a presumed solitary metastatic lesion from lung cancer.

PET scanning may be considered **medically necessary** in staging of small-cell lung cancer if limited stage is suspected based on standard imaging.

PET scanning is considered **investigational** in staging of small-cell lung cancer if extensive stage is established and in all other aspects of managing small-cell lung cancer.

POLICY GUIDELINES

Patient Selection

As with any imaging technique, the medical necessity of positron emission tomography (PET) scanning depends in part on what imaging techniques are used before or after the PET scanning. Due to its expense, PET scanning is typically considered after other techniques, such as computed tomography (CT), magnetic resonance imaging (MRI), or ultrasonography, provide inconclusive or discordant results. Thus, PET should be considered for the medically necessary indications above only when standard imaging (eg, CT, MRI) is inconclusive or not indicated.

Patient selection criteria for PET scanning may also be complex. For example, it may be difficult to determine from claims data whether a PET scan in a patient with malignant melanoma is being done primarily to evaluate extranodal disease or regional lymph nodes. Similarly, it may be difficult to determine whether a PET scan in a patient with colorectal cancer is being performed to detect hepatic disease or evaluate local recurrence. Due to the complicated hierarchy of imaging options in individuals with malignancy and complex patient selection criteria, a possible implementation strategy for this policy is its use for retrospective review, possibly focusing on cases with multiple imaging tests, including PET scans.

Use of PET scanning for surveillance as described in the policy statement and policy rationale refers to the use of PET to detect disease in asymptomatic individuals at various intervals. This is not the same as the use of PET for detecting recurrent disease in symptomatic individuals; these applications of PET are considered within tumor-specific categories in the policy statements.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

A number of radiopharmaceuticals have been granted approval by the FDA, to be used with PET for various cancer-related indications, however none are specific to bone or soft tissue sarcoma. Fluorine-18 fluorodeoxyglucose (FDG) is approved for use in suspected or existing diagnosis of cancer, all types.

RATIONALE

Summary of Evidence

Non-Small-Cell Lung Cancer

For individuals who have suspected non-small-cell lung cancer (NSCLC) and inconclusive results from other imaging techniques who receive FDG-PET or FDG-PET/CT, the evidence includes several meta-analyses. Relevant outcome is test validity. Pooled analyses have shown that PET and PET/CT have better diagnostic performance than conventional imaging techniques. Clinical guidelines include PET/CT to inform management decisions that may offer clinical benefit. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have diagnosed NSCLC and in need of staging or restaging information who receive FDG-PET or FDG-PET/CT, the evidence includes several meta-analyses. Relevant outcome is test validity. Pooled analyses have shown that PET and PET/CT have better diagnostic performance than conventional imaging techniques. Clinical guidelines include PET/CT to inform management decisions that may offer clinical benefit. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have suspected NSCLC or who are asymptomatic after completing NSCLC treatment who receive FDG-PET or FDG-PET/CT, there is no evidence. Relevant outcome is test validity. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Small-Cell Lung Cancer

For individuals with diagnosed small-cell lung cancer (SCLC) and in need of staging or restaging information who receive FDG-PET or FDG-PET/CT, the evidence includes systematic reviews and meta-analyses. Relevant outcome is test validity. While the quality of the studies was considered low, PET and PET/CT can be considered for staging or restaging in individuals with SCLC if a limited stage is suspected. Clinical guidelines include PET/CT to inform management decisions that may offer clinical benefit. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have suspected SCLC or who are asymptomatic after completing SCLC treatment who receive FDG-PET or FDG-PET/CT, there is no evidence. Relevant outcome is test validity. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

Current National Comprehensive Cancer Network, American College of Radiology, and other relevant U.S.-based guidelines are summarized in each section of the Rationale.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

The Medicare coverage policy on positron emission tomography scans, effective for claims with dates of service on and after June 11, 2013, is summarized in Table 1.¹⁵

Table 1. National FDG PET Coverage for Oncologic Conditions

Effective for claims with dates of service on and after June 11, 2013, the chart below summarizes national FDG PET coverage for oncologic conditions:

FDG PET for Cancers by Tumor Type	Initial Treatment Strategy (formerly "diagnosis" & "staging")	Subsequent Treatment Strategy (formerly "restaging" & "monitoring response to treatment")
Colorectal	Cover	Cover
Esophagus	Cover	Cover
Head and Neck (not thyroid, CNS)	Cover	Cover
Lymphoma	Cover	Cover
Non-small cell lung	Cover	Cover
Ovary	Cover	Cover
Brain	Cover	Cover
Cervix	Cover with exceptions *	Cover
Small cell lung	Cover	Cover
Soft tissue sarcoma	Cover	Cover
Pancreas	Cover	Cover
Testes	Cover	Cover
Prostate	Non-cover	Cover
Thyroid	Cover	Cover
Breast (male and female)	Cover with exceptions *	Cover
Melanoma	Cover with exceptions *	Cover
All other solid tumors	Cover	Cover
Myeloma	Cover	Cover
All other cancers not listed	Cover	Cover

*Cervix: Nationally non-covered for the initial diagnosis of cervical cancer related to initial anti-tumor treatment strategy. All other indications for initial anti-tumor treatment strategy for cervical cancer are nationally covered.

*Breast: Nationally non-covered for initial diagnosis and/or staging of axillary lymph nodes. Nationally covered for initial staging of metastatic disease. All other indications for initial anti-tumor treatment strategy for breast cancer are nationally covered.

*Melanoma: Nationally non-covered for initial staging of regional lymph nodes. All other indications for initial anti-tumor treatment strategy for melanoma are nationally covered.

REFERENCES

1. Barger RL, Nandalur KR. Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis. *Acad Radiol.* Feb 2012; 19(2): 153-8. PMID 22104289
2. Blue Cross Blue Shield Association Technology Evaluation Center (TEC). FDG Positron Emission Tomography for Non-CNS Cancers. *Technol Eval Cent Assess.* 1997;12(3).

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

3. Brea TP, Ravia AR, Villamor JMC, et al. Use of Magnetic Resonance Imaging for N-Staging in Patients with Non-Small Cell Lung Cancer. A Systematic Review. Arch Bronconeumol (Engl Ed). Jan 2019; 55(1): 9-16. PMID 29803524
4. Ruilong Z, Daohai X, Li G, et al. Diagnostic value of 18F-FDG-PET/CT for the evaluation of solitary pulmonary nodules: a systematic review and meta-analysis. Nucl Med Commun. Jan 2017; 38(1): 67-75. PMID 27741214
5. He YQ, Gong HL, Deng YF, et al. Diagnostic efficacy of PET and PET/CT for recurrent lung cancer: a meta-analysis. Acta Radiol. Apr 2014; 55(3): 309-17. PMID 24081215
6. Seol HY, Kim YS, Kim SJ. Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer. Oncology. 2021; 99(2): 96-104. PMID 32980838
7. Li Y, Jin G, Su D. Comparison of Gadolinium-enhanced MRI and 18FDG PET/PET-CT for the diagnosis of brain metastases in lung cancer patients: A meta-analysis of 5 prospective studies. Oncotarget. May 30 2017; 8(22): 35743-35749. PMID 28415747
8. Li J, Xu W, Kong F, et al. Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients. Surg Oncol. Sep 2013; 22(3): 151-5. PMID 23664848
9. de Groot PM, Chung JH, Ackman JB, et al. ACR Appropriateness Criteria Noninvasive Clinical Staging of Primary Lung Cancer. J Am Coll Radiol. May 2019; 16(5S): S184-S195. PMID 31054745
10. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Version 4.2023. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed October 31, 2023
11. Lu YY, Chen JH, Liang JA, et al. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. Nucl Med Commun. Jul 2014; 35(7): 697-703. PMID 24694775
12. Ruben JD, Ball DL. The efficacy of PET staging for small-cell lung cancer: a systematic review and cost analysis in the Australian setting. J Thorac Oncol. Jun 2012; 7(6): 1015-20. PMID 22534816
13. Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. Apr 04 2000; 132(7): 566-77. PMID 10744594
14. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Small Cell Lung Cancer. Version 1.2024. https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf. Accessed October 30, 2023
15. Centers for Medicare & Medicaid Services (CMS). 2013. Pub 100-03 National Coverage Determination (NCD) for Positron Emission Tomography (FDG) for Oncologic Conditions (220.6.17). <https://tinyurl.com/7hc7hvpr>. Accessed October 30, 2023.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
September 2024	New policy- Add to Radiology/Interventional Radiology section	Policy created by separating out lung cancer indications from policy 6.01.26. Policy revised with literature review through October 13, 2023. No references added. Policy statements unchanged.